NCT00412828View on ClinicalTrials.gov

A Phase I/II Study of CR011-vcMMAE in Subjects With Unresectable Stage III or Stage IV Melanoma

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

117

Participants

Timeline

Start Date

June 30, 2006

Primary Completion Date

December 31, 2010

Study Completion Date

May 31, 2011

Conditions
Unresectable Stage III or Stage IV Melanoma
Interventions
DRUG

CR011-vcMMAE

administered as an intravenous infusion of 250 mL over 90 min

Trial Locations (4)

10016

New York University Medical Center, New York

77030

M.D. Anderson Cancer Center, Houston

90404

Angeles Clinic and Research Institute, Santa Monica

06520

Yale University, New Haven

Sponsors
All Listed Sponsors
lead

CuraGen Corporation

INDUSTRY

NCT00412828 - A Phase I/II Study of CR011-vcMMAE in Subjects With Unresectable Stage III or Stage IV Melanoma | Biotech Hunter | Biotech Hunter